Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

101 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tranexamic Acid in Revision Total Joint Arthroplasty

NCT02877381

Revision Total Knee Arthroplasty Revision Total Hip Arthroplasty Acute Blood Loss Anemia

COMPLETED PHASE4

Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical

NCT01940523

Osteoarthritis

COMPLETED PHASE4

Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty

NCT01370460

Acute Blood Loss Anemia Osteoarthritis, Knee

COMPLETED PHASE2

Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty

NCT06208267

Postoperative Bleeding

RECRUITING NA

Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty

NCT02393963

Osteoarthritis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthroplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral tranexamic acid

Group Type EXPERIMENTAL

Oral Tranexamic Acid

Intervention Type DRUG

Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3

Control Group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral Tranexamic Acid

Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged \> 18 years (All women of childbearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
* Written informed consent
* Patients undergoing primary THA diagnosis of end-stage osteoarthritis
* Patients receiving spinal anesthesia
* Patients being discharged on postoperative day 1

Exclusion Criteria

* Patients with a TXA allergy
* Patients undergoing revision procedures
* Patients undergoing primary THA for a diagnosis other than end-stage osteoarthritis
* Patients receiving general anesthesia
* Patients being discharged on the same day of surgery
* Cancer patients
* Patients with a history of prior VTE event
* Patients on preoperative anticoagulants other than ASA
* Pregnant patients (All women of child bearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
* Female patients who are on hormonal contraception
* Patients with history of retinal vein or artery occlusion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No